Intranasal Glutathione in Parkinson's Disease
Published November 17, 2010
About the Study
Parkinson's disease (PD) is considered a progressive and irreversible neurodegenerative disease. Current therapies improve disease symptoms, however, none alter the underlying degenerative course. Research suggests the loss of brain glutathione, a powerful antioxidant, is one of the earliest changes to occur in the brain of PD patients and the magnitude of glutathione depletion parallels the severity of PD. This study will look at the use of intranasal glutathione in PD patients to determine safety, tolerability, and impact on PD symptoms.
Project Overview
Status
Active
Study area
Neurology
Principal investigator
Laurie Mischley, ND
Project period
January 2010 – December 2014
Completed date (for sorting)
Wednesday, April 30, 2014